2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

2:30PM-4:00PM: Abstract Number: 3090

Fibromyalgia Predicts Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients

Fibromyalgia: Clinical Issues

2:30PM-4:00PM: Abstract Number: 3121

Gender Differences in Patient Reported Outcomes (PROs) in Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis - CoMorbidities

2:30PM-4:00PM: Abstract Number: 3088

Genome Wide Expression Analyses Reveal Potentially Novel Drug Targets in Fibromyalgia

Fibromyalgia: Clinical Issues

2:30PM-4:00PM: Abstract Number: 3128

Genome-Wide DNA Methylation Analysis in Blood and Dermal Fibroblasts from Twin Pairs Discordant for Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II

2:30PM-4:00PM: Abstract Number: 3146

Health Related Quality of Life in Adults with JIA – a 30 Year Longitudinal Study

ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

2:30PM-4:00PM: Abstract Number: 3116

High Level of Inflammation Predicts the Development of Diabetes Mellitus in Patients with Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis - CoMorbidities

2:30PM-4:00PM: Abstract Number: 3132

Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis Via Repressing Pro-Angiogenic Factors

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II

2:30PM-4:00PM: Abstract Number: 3080

Histone H2AX Phosphorylation As a Measure of DNA Double Strand Breaks and a Marker of Environmental Stress and Disease Activity in Lupus

2015 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3114

Immunogenicity of Subcutaneous and Intravenous Tocilizumab As Monotherapy or in Combination with Dmards

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy V: Immunogenecity

2:30PM-4:00PM: Abstract Number: 3136

Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics II

2:30PM-4:00PM: Abstract Number: 3110

In the Multicenter Randomized Controlled Rotation or Change Trial, a Non-TNF Targeted Therapy Has a Higher Efficacy Than a Second Anti-TNF at 3, 6 and 12 Months

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy V: Immunogenecity

2:30PM-4:00PM: Abstract Number: 3112

Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy V: Immunogenecity

2:30PM-4:00PM: Abstract Number: 3135

Incidences and Predictors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal Study

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics II

2:30PM-4:00PM: Abstract Number: 3102

Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in Early Aggressive RA, Regardless of Treatment Strategy

Rheumatoid Arthritis - Clinical Aspects IV: Biomarkers, Disease Progression and Treatment Response

2:30PM-4:00PM: Abstract Number: 3095

Initial Results of a Pilot Juvenile Localized Scleroderma (jLS) Comparative Effectiveness Study

Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].